A Phase 2 interventional study of GLPG0634 and Placebo in Crohn's Disease, sponsored by Galapagos NV. Completed at 63 sites in 9 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-02-23.
Sponsored by Galapagos NV · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Crohn Disease with a site in Russian Federation — 2 open to participants now, 2 under way, none of them phase 3. Crohn Disease · Russian Federation.
Among the 54 studies in Crohn Disease with a site in Russian Federation, this one is the 34th largest by enrollment of the 51 interventional ones that give a count, is the only one that started in 2014, is one of 15 in phase 2, and was the 15th registered.
1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →2 of the 54 studies in Crohn Disease with a site in Russian Federation are open now. Recruiting first, the newest first:
Biocad · Sites in Russian Federation
Ages 18–45 · Men only · Healthy volunteers
Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department · Sites in Russian Federation
Ages 18+
A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 175 is above the median of 67 across 1,261 interventional studies indexed under Crohn Disease.
Median enrollment 310 across the 51 interventional studies, 1,731 across the 3 observational. Of the 49 that completed or were terminated, 40 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
51 of 54 have an industry lead sponsor. The 10 most frequent:
This study is registered under Galapagos NV, one of the names counted as Lakefront Biotherapeutics NV. Under that name alone:
Galapagos NV is the lead sponsor of 103 studies on the registry; none are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 11 (79%) have results posted.
Lakefront Biotherapeutics NV has 3 studies filed under Crohn Disease — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 54 studies in Crohn Disease with a site in Russian Federation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2 tablets of 100 mg GLPG0634 in the morning
Drug: GLPG0634
1 tablet of 100 mg GLPG0634 and 1 placebo tablet in the morning
Drug: GLPG0634 · Drug: Placebo
2 placebo tablets in the morning
Drug: Placebo
100 mg oral tablet, intake once daily for 20 weeks
Also known as: GLPG0634 tablets
placebo oral tablets, intake once daily for 20 weeks
Also known as: Placebo tablets
Percentage of subjects achieving clinical remission at Week 10
Percentage of subjects achieving clinical remission as defined by a Crohn's Disease Activity Index score \< 150 points
Time frame: Week 10
Percentage of subjects achieving clinical remission
Percentage of subjects achieving clinical remission as defined by a Crohn's Disease Activity Index score \< 150 points, assessed at every visit
Time frame: Up to Week 20
Percentage of subjects achieving clinical response
Percentage of subjects achieving clinical response as defined by a decrease in Crohn's Disease Activity Index score of at least 100 points, assessed at every visit
Time frame: Up to Week 20
Percentage of subjects achieving endoscopic remission at Week 10
Percentage of subjects achieving endoscopic remission as defined by a reduction of Simplified Endoscopy Score for Crohn's Disease (SES-CD) score ≤ 4, with ulcerated surface subscore no greater than 1 in any segment at Week 10
Time frame: Week 10
Percentage of subjects achieving endoscopic response at Week 10
Percentage of subjects achieving endoscopic response as defined by a reduction of Simplified Endoscopy Score for Crohn's Disease (SES-CD) score by at least 50% from Screening at Week 10
Time frame: Week 10
Percentage of subjects achieving mucosal healing at Week 10
Percentage of subjects achieving mucosal healing as defined by a Simplified Endoscopy Score for Crohn's Disease (SES-CD) score equal to 0 at Week 10
Time frame: Week 10
Change from Baseline in Crohn's Disease Activity Index score
Change from Baseline in Crohn's Disease Activity Index score, assessed at every visit
Time frame: Up to Week 20
Change from Screening in endoscopic score
Change from Screening in endoscopic Simplified Endoscopy Score for Crohn's Disease (SES-CD) score at Week 10
Time frame: Week 10
Change from Screening in histopathology biopsy score
Change from Screening in histopathology biopsy score at Week 10
Time frame: Week 10
Change from Baseline in Subjects' Quality of Life (based on the Inflammatory Bowel Disease Questionnaire (IBDQ) questionnaire score)
Change from Baseline in Subjects' Quality of Life based on the IBDQ questionnaire score at Week 10 and Week 20
Time frame: Up to Week 20
The number of subjects with adverse events
To evaluate the safety and tolerability of GLPG0634 in comparison with placebo in terms of adverse events (AEs)
Time frame: From screening up to 2 weeks after last dose
The number of subjects with abnormal lab tests
To evaluate the safety and tolerability of GLPG0634 in comparison with placebo in terms laboratory test abnormalities
Time frame: From screening up to 2 weeks after last dose
The number of subjects with abnormal vital signs
To evaluate the safety and tolerability of GLPG0634 in comparison with placebo in terms of abnormalities in vital signs
Time frame: From screening up to 2 weeks after last dose
The number of subjects with abnormal ECG
To evaluate the safety and tolerability of GLPG0634 in comparison with placebo in terms of abnormalities in electrocardiogram (ECG)
Time frame: From screening up to 2 weeks after last dose
The plasma levels of GLPG0634 and its metabolite
To characterize the pharmacokinetics (PK) of GLPG0634 and its metabolite by measuring the amount in plasma from Week 2 up to Week 20 at every visit
Time frame: Up to Week 20
The change versus Baseline in levels of immune- and inflammation-related parameters in whole blood and serum
To characterize the pharmacodynamics (PD) of GLPG0634 and its metabolite by measuring the levels of immune- and inflammation-related parameters in whole blood and serum
Time frame: Up to Week 20
The change versus Baseline in levels of faecal calprotectin
To characterize the pharmacodynamics (PD) of GLPG0634 and its metabolite by measuring the levels of faecal calprotectin
Time frame: Up to Week 20
The change versus Baseline in microbial communities in stool samples
To characterize the effects of GLPG0634 and its metabolite on the microbial communities by measuring the levels of predominant microbiota in stool samples
Time frame: Up to Week 10
The record gives a start of Feb 2014, a primary completion of Nov 2015 and a completion of Feb 2016. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GLPG0634